Jamy Omer, Yaghmour George, Hare Felicia, Martin Michael G
Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, U.S.A.
Department of Hematology/Oncology, The West Clinic, University of Tennessee Health Science Center, Memphis, TN, U.S.A.
Anticancer Res. 2015 May;35(5):3091-5.
Primary small cell carcinoma of the ovary (SCCO) is rare, making prognosis and outcomes largely undefined.
Using case listing session of SEER 18 (1973-2010), we examined outcomes for patients with SCCO. Analyses were conducted with SEER(*)Stat 8.1.2, Microsoft Excel 2007 and GraphPad Prism 6. Comparisons were made using the Chi-square test and log-rank test (Mantel-Cox) and all p-values were 2-sided.
One hundred and eighty-one patients with SCCO with staging information were identified with a median age of 37 (range=10-91). Twenty-nine patients (15%) had localized, 19 (11%) regional and 133 (74%) distant disease at presentation. All patients with localized and 95% of patients with regional disease had surgery. The extent of surgery did not influence outcomes. Median overall survival (OS) varied by stage (67 months vs. 12 months vs. 9 months, p<0.001). Radiation was rarely used in localized (1 patient) or regional disease (3 patients). For comparison, 81,933 cases of SCLC were identified from the same database with a median age of 68; 8% of small cell lung cancer (SCLC) patients had localized, 29% regional and 63% distant disease. Outcomes were superior for patients with SCCO with localized disease (67 months vs. 16 months, p<0.001) but there was no clinically meaningful difference in patients with regional (12 months vs. 13 months, p=0.675) or distant disease (9 months vs. 7 months, p<0.001).
SCCO presents at a younger age than SCLC but has a similar stage distribution. Patients with localized SCCO have a more favorable prognosis than patients with SCLC but patients with regional and distant disease have similar outcomes.
原发性卵巢小细胞癌（SCCO）较为罕见，其预后和转归在很大程度上尚不明确。
利用监测、流行病学与最终结果（SEER）18数据库（1973 - 2010年）的病例列表会议，我们研究了SCCO患者的转归情况。分析使用SEER(*)Stat 8.1.2、Microsoft Excel 2007和GraphPad Prism 6软件进行。采用卡方检验和对数秩检验（Mantel - Cox检验）进行比较，所有p值均为双侧。
共识别出181例有分期信息的SCCO患者，中位年龄为37岁（范围 = 10 - 91岁）。29例（15%）患者初诊时为局限性病变，19例（11%）为区域性病变，133例（74%）为远处病变。所有局限性病变患者及95%的区域性病变患者接受了手术治疗。手术范围不影响转归。中位总生存期（OS）因分期而异（67个月对12个月对9个月，p < 0.001）。局限性病变（1例患者）或区域性病变（3例患者）很少使用放疗。作为对照，从同一数据库中识别出81,933例小细胞肺癌（SCLC）病例，中位年龄为68岁；8%的小细胞肺癌患者为局限性病变，29%为区域性病变，63%为远处病变。局限性病变的SCCO患者转归优于SCLC患者（67个月对16个月，p < 0.001），但区域性病变（12个月对13个月，p = 0.675）或远处病变（9个月对7个月，p < 0.001）患者的转归在临床上无显著差异。
SCCO患者发病年龄比SCLC患者年轻，但分期分布相似。局限性SCCO患者的预后优于SCLC患者，但区域性和远处病变患者的转归相似。
